Celyad Oncology S.A.
CYAD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | – | $7 | $12 | $30 |
| Short-Term Investments | – | $0 | $0 | $0 |
| Receivables | – | $0 | $1 | $2 |
| Inventory | – | $0 | $0 | $0 |
| Other Curr. Assets | – | $4 | $1 | $2 |
| Total Curr. Assets | – | $11 | $15 | $34 |
| Property Plant & Equip (Net) | – | $2 | $0 | $3 |
| Goodwill | – | $0 | $0 | $1 |
| Intangibles | – | $0 | $1 | $35 |
| Long-Term Investments | – | $0 | $0 | $2 |
| Tax Assets | – | $0 | $0 | -$2 |
| Other NC Assets | – | $3 | $4 | $6 |
| Total NC Assets | – | $5 | $5 | $46 |
| Other Assets | – | $0 | $0 | $0 |
| Total Assets | – | $16 | $20 | $80 |
| Liabilities | – | – | – | – |
| Payables | – | $1 | $5 | $7 |
| Short-Term Debt | – | $0 | $0 | $1 |
| Tax Payable | – | $0 | $0 | $0 |
| Deferred Revenue | – | $0 | $1 | $1 |
| Other Curr. Liab. | – | $2 | $6 | $6 |
| Total Curr. Liab. | – | $3 | $10 | $14 |
| LT Debt | – | $1 | $0 | $2 |
| Deferred Rev, NC | – | $0 | $5 | $6 |
| Deferred Tax Liab, NC | – | $0 | $0 | $15 |
| Other NC Liab. | – | $6 | $0 | $0 |
| Total NC Liab. | – | $7 | $5 | $22 |
| Other Liabilities | – | $0 | $0 | $0 |
| Cap. Leases | – | $1 | $0 | $3 |
| Total Liabilities | – | $10 | $15 | $36 |
| Equity | – | – | – | – |
| Pref Stock | – | $0 | $0 | $0 |
| Common Stock | – | $33 | $79 | $79 |
| Retained Earnings | – | -$358 | -$350 | -$309 |
| AOCI | – | $332 | $269 | $268 |
| Other Equity | – | $0 | $6 | $6 |
| Total Equity | – | $6 | $4 | $44 |
| Supplemental Information | – | – | – | – |
| Minority Interest | – | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | – | $16 | $20 | $80 |
| Net Debt | $0 | -$6 | -$12 | -$27 |